Lung Therapeutics, Inc. Headquartered in Austin, Texas, the company is dedicated to developing novel therapies for underserved pulmonary indications with unmet medical needs. Lung Therapeutics has a robust pipeline of proprietary drugs designed to significantly improve outcomes compared to existing treatments.

Their lead drug candidate, LTI-01, is undergoing clinical development for Loculated Pleural Effusion (LPE). This condition occurs when scar tissue traps fluid in the pleural cavity, leading to a buildup that hampers drainage. LTI-01 has shown promising signs of efficacy in a completed clinical trial and has received Orphan Drug Designations and Fast Track Designation in the US.

In addition to LTI-01, Lung Therapeutics is also developing LTI-03, a groundbreaking peptide drug targeting the survival of lung epithelial cells and inhibiting fibroblast proliferation in Idiopathic Pulmonary Fibrosis (IPF) patients. IPF is a chronic lung disease characterized by progressive scarring and impaired lung function. With their innovative approach and dedication to improving outcomes for patients, Lung Therapeutics is at the forefront of transforming the field of lung disease therapeutics